Related Experiment Video
Updated: Jun 6, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
PD-1 negatively regulates interleukin-12 expression by limiting STAT-1 phosphorylation in monocytes/macrophages
Cheng J Ma1, Lei Ni, Ying Zhang
1Division of Infectious Diseases, Department of Internal Medicine, James H. Quillen College of Medicine, East Tennessee State University, Johnson City, TN 37614, USA.
Insights
Hepatitis C virus (HCV) evades immunity, suppressing interleukin-12 (IL-12) from monocytes/macrophages. PD-1 pathway inhibition limits IL-12 by reducing STAT-1 activation, suggesting a therapeutic target for chronic HCV infection.
Area of Science:
- Immunology
- Virology
- Molecular Biology
Background:
- Chronic Hepatitis C virus (HCV) infection is characterized by immune evasion and suppressed interleukin-12 (IL-12) production by monocytes/macrophages (M/Mφ).
- Programmed death-1 (PD-1) is an inhibitory receptor crucial for T-cell suppression in chronic viral infections.
Purpose of the Study:
- To investigate the role of the PD-1/PD-L1 pathway in regulating IL-12 production by M/Mφ during chronic HCV infection.
- To explore the relationship between PD-1 expression and IL-12 suppression in M/Mφ.
Main Methods:
- Flow cytometry was used to analyze PD-1, PD-L1 expression, and IL-12 production in M/Mφ from HCV-infected, resolved, and healthy individuals.
- Intracellular STAT-1 phosphorylation was assessed to evaluate the janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway activation.
Main Results:
- HCV-infected subjects showed up-regulated PD-1/PD-L1 expression and suppressed Toll-like receptor (TLR)-mediated IL-12 production in M/Mφ compared to controls.
- PD-1 up-regulation was inversely correlated with IL-12 inhibition, and M/Mφ exhibited impaired STAT-1 phosphorylation.
- HCV treatment or ex vivo PD-1/PD-L1 blockade restored IL-12 production and STAT-1 activation.
Conclusions:
- The PD-1 inhibitory pathway negatively regulates M/Mφ IL-12 expression, potentially by limiting STAT-1 phosphorylation during chronic HCV infection.
- Targeting the PD-1/PD-L1 pathway may represent a therapeutic strategy to restore immune function in chronic HCV.
Abstract:
Hepatitis C virus (HCV) is remarkably efficient at evading host immunity to establish chronic infection. During chronic HCV infection, interleukin-12 (IL-12) produced by monocytes/macrophages (M/Mφ) is significantly suppressed. Programmed death-1 (PD-1), an inhibitory receptor on immune cells, plays a pivotal role in suppressing T-cell responses during chronic viral infection. To determine whether PD-1 regulates IL-12 production by M/Mφ during chronic HCV infection, we examined the expressions of PD-1, its ligand PDL-1, and their relationship with IL-12 production in M/Mφ from HCV-infected, HCV-resolved, and healthy subjects by flow cytometry. Toll-like receptor (TLR) -mediated IL-12 production by M/Mφ was selectively suppressed, while PD-1/PDL-1 expressions were up-regulated, in HCV-infected subjects compared with HCV-resolved or healthy subjects. Up-regulation of PD-1 was inversely associated with the degree of IL-12 inhibition in HCV infection. Interestingly, the reduced response of M/Mφ from HCV-infected individuals to TLR ligands appeared not to be the result of a lack of the ability to sense pathogen, but to an impaired activation of intracellular janus kinase/signal transducer and activator of transfection (STAT) pathway as represented by inhibited STAT-1 phosphorylation in M/Mφ from HCV-infected individuals compared with HCV-negative subjects. Successful HCV treatment with pegylated interferon/ribavirin or blocking PD-1/PDL-1 engagement ex vivo led to reduced PD-1 expression and improved IL-12 production as well as STAT-1 activation in M/Mφ from HCV-infected individuals. These results suggest that the PD-1 inhibitory pathway may negatively regulate IL-12 expression by limiting STAT-1 phosphorylation in M/Mφ during chronic HCV infection.
More Related Videos
Related Concept Videos
The JAK-STAT Signaling Pathway
Inhibitors of Viral Protein Synthesis
Hepatitis
Gastritis II: Pathophysiology

